AL-LAD

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin describes the dose range of AL-LAD as 80 to 160μg and its duration as 6 to 8hours. In other publications however, Shulgin listed its dose range as 50 to 150μg. A typical or moderate dose may be around 100μg. The drug appears to be roughly equipotent with LSD, which has a listed dose range of 50 to 200μg. AL-LAD's duration appears to be shorter than that of LSD, which is said to have a duration of 8 to 12hours. The onset of AL-LAD has been reported to be within 15 to 20minutes, but others reported a slower and more gradual onset building up over a few hours. It is also reported to have a very long "down-ramp" of effects.

AL-LAD has been described as producing similar effects to LSD and as being "really trippy" similarly, but as lacking the "vaguely sinister push" of LSD. In addition, it has been reported to have less visual distortion than LSD. The experience has been described as "simply beautiful". Its effects have been reported to include waves of intensification, no closed-eye visuals to superb mental imagery, mild visual distortion, open-eye visuals including floors melting and patterns on walls and ceilings flowing, some time dilation, separation from surrounding world, loss of contact with body, body feeling "blob-like", feeling stoned, music and erotic enhancement, clear thinking and good interpretation, mental and physical excitation, mood fluctuations, emotional lability, crying, opening up of repressed feelings, and in one case social distance and avoidance. Some individuals specifically reported no fear, panic, or body disturbance.

Interactions

Pharmacology

Pharmacodynamics

AL-LAD has been found to interact with the serotonin 5-HT1 and 5-HT2 receptors and with the dopamine D1 and D2 receptors. It is known to act as a potent full agonist of the serotonin 5-HT2A receptor.

The drug was about 3.5-fold more potent than LSD in substituting for LSD in drug discrimination tests in rodents. Conversely however, AL-LAD was similar in potency to LSD in humans. AL-LAD produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. It was slightly less potent than LSD in producing the head-twitch response in rodents.

Pharmacokinetics

The in-vitro metabolism of AL-LAD has been studied.

Chemistry

AL-LAD, also known as 6-allyl-6-nor-LSD or as 6-allyl-6-nor-N,N-diethyllysergamide, is a synthetic substituted lysergamide and a 6-substituted derivative of nor-LSD (LAD).

Detection

AL-LAD does not cause a color change with the Marquis, Mecke or Mandelin reagents, but does cause the Ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.

Synthesis

The chemical synthesis of AL-LAD has been described. It is starting from nor-LSD as a precursor, using allyl bromide as a reactant.

Analogues

AL-LAD is closely related to other 6-substituted lysergamides such as LSD (METH-LAD), ETH-LAD, PRO-LAD, and MAL-LAD, among others. Ester prodrugs of AL-LAD include 1P-AL-LAD, 1cP-AL-LAD, and 1T-AL-LAD.

History

AL-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues in 1976. Subsequently, it was further studied by Andrew J. Hoffman and David E. Nichols in 1985. Alexander Shulgin described the effects of AL-LAD in humans in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug in Europe by 2015.

Society and culture

Legal status

International

AL-LAD is not scheduled by the United Nations' Convention on Psychotropic Substances overcome is legal ever that doesn't be sold for recreational usage, could be sold for medical or research purposes like a research chemical..

Canada

AL-LAD is not a controlled substance in Canada as of 2025.

Denmark

AL-LAD is illegal in Denmark.

Finland

Listed in a decree of the government's psychoactive substances banned from the consumer market.

France

AL-LAD is illegal in France.

Latvia

AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analogue due to an amendment made on June 1, 2015.

Sweden

The Riksdag added AL-LAD to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.

Switzerland

AL-LAD is illegal in Switzerland.

United Kingdom

AL-LAD is illegal in the UK. On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

United States

AL-LAD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

References

References

1. "#1 AL-LAD".
2. (20 May 2021). "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". Journal officiel de la République française.
3. (1991). "Biochemistry and Physiology of Substance Abuse". CRC Press.
4. (January 2017). "6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis.
5. (1976). "Lysergic Acid Diethylamideおよび関連化合物に関する研究(第4報)Norlysergic Acidの各種Amide誘導体ならびに関連化合物の合成". Yakugaku Zasshi.
6. (23 October 2018). "2015 Annual Reports on the implementation of Council Decision 2005/387/JHA".
7. (March 2023). "Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities". Drug Test Anal.
8. (July 2023). "Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products". Forensic Toxicol.
9. (July 2025). "Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet". Forensic Toxicol.
10. (April 2025). "Synthesis and analytical characterization of 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD)". Drug Test Anal.
11. (1994). "Structure-activity relationships of the classic hallucinogens and their analogs". NIDA Res Monogr.
12. (2003). "Hallucinogens: A Forensic Drug Handbook". Elsevier Science.
13. (April 2016). "Psychedelics". Pharmacol Rev.
14. (1997). "[[TiHKAL: The Continuation]]". Transform Press.
15. (2017). "Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs". Front Psychiatry.
16. (August 1987). "Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Purdue University.
17. (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology.
18. (16 January 2013). "Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics". Purdue University.
19. (1994). "Lysergamides revisited". NIDA Research Monograph.
20. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
21. (2018). "Behavioral Neurobiology of Psychedelic Drugs".
22. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Anal Bioanal Chem.
23. (August 2022). "Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD". Drug Test Anal.
24. Ecstasydata. "AL-LAD (Not sold as ecstasy)". EcstasyData.org.
25. (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". J Med Chem.
26. "Conventions".
27. "Controlled Drugs and Substances Act".
28. (September 2015). "Lists of euphoriant substances". The Danish Medicines Agency.
29. "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 166/2016".
30. "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 225/2017".
31. (May 2021). "Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". Republique Française.
32. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem".
33. "Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m.". Lakemedelsverket.
34. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.
35. ACMD. (10 June 2014). "Update of the Generic Definition for Tryptamines". UK Home Office.
36. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.
37. "Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary".